Mechanisms of chemical carcinogenesis: recent advances

Food Additives and Contaminants
P E Fournier, G Thomas

Abstract

The carcinogenetic risk assessment of veterinary drugs has to be envisaged as part of food toxicology. The authors review the recent discoveries which have proved significant for the toxicologist. Tumours arise from an inherited transformation of normal cells through genotoxic, perigenetic and epigenetic processes. Genotoxic mechanisms are best understood and have led to the development of short-term reference tests. The biochemistry of DNA alterations is being unravelled and permits quantitative estimation of carcinogenetic potencies. Work on the role of oncogenes is providing new clues to the understanding the mechanisms of chemical carcinogenesis. Perigenetic processes deal mainly with DNA repair systems and emphasize the complexity of human genome dynamics. Experimental findings about epigenetic mechanisms are still inconclusive as to their practical implications. Abnormal expression of HLA-antigens at the surface of neoplastic cells has been reported, but its significance is still unknown. In conclusion, the main source of progress in toxicology undoubtedly comes from molecular biology, but experimental results must be interpreted with caution if practical issues are to be derived from them.

References

Sep 1, 1979·Mutation Research·M HollsteinW W Nichols
May 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·S J CollinsR C Gallo
Apr 20, 1979·Science·F Crick
Jan 1, 1979·Annual Review of Biochemistry·P C HanawaltC A Smith
Oct 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·P MoreauR Devoret
Aug 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·B N AmesF D Lee
Dec 1, 1972·Cancer·B D Clarkson
Jan 1, 1980·Advances in Cancer Research·E Farber, R Cameron
Jan 29, 1981·Nature·J Cairns
Feb 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·M ShefferyP A Marks
Jul 15, 1983·Science·J J Yunis
Jul 21, 1983·Nature·P H Duesberg
Aug 18, 1983·The New England Journal of Medicine·T G Krontiris
Jan 1, 1983·Annual Review of Biochemistry·J M Bishop
Jun 1, 1981·Mutation Research·B J KilbeyE W Vogel
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·P QuillardetM Hofnung
Jan 14, 1983·Science·J L Marx
Jun 1, 1981·Journal of the National Cancer Institute·S H Moolgavkar, A G Knudson
Jan 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·Z ChenP A Marks
Sep 15, 1981·International Journal of Cancer. Journal International Du Cancer·J Lotem, L Sachs

❮ Previous
Next ❯

Citations

Mar 1, 1995·Pharmacology & Therapeutics·R E PowersI M Modlin
Aug 1, 1989·Quarterly Reviews of Biophysics·A R Holzwarth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.